Due to this, it can be hypothesized that, in the case of PCNSL acquiring ibrutinib resistance through CD79B mutations, the addition of PI3K/mTOR inhibitors could reestablish response to therapy [5]. The gene discussed is MTOR; the disease is primary central nervous system lymphoma.